[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2061435T3 - Procedimiento y agentes para la inhibicion del envejecimiento de las proteinas. - Google Patents

Procedimiento y agentes para la inhibicion del envejecimiento de las proteinas.

Info

Publication number
ES2061435T3
ES2061435T3 ES86115332T ES86115332T ES2061435T3 ES 2061435 T3 ES2061435 T3 ES 2061435T3 ES 86115332 T ES86115332 T ES 86115332T ES 86115332 T ES86115332 T ES 86115332T ES 2061435 T3 ES2061435 T3 ES 2061435T3
Authority
ES
Spain
Prior art keywords
aging
composition
inhibiting
agents
glycosylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86115332T
Other languages
English (en)
Inventor
Anthony Cerami
Peter Ulrich
Michael Brownlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2061435T3 publication Critical patent/ES2061435T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PREPARACIONES Y METODOS PARA INHIBIR EL ENVEJECIMIENTO DE LAS PROTEINAS. EN ELLA SE DESCRIBE UNA PREPARACION QUE CONTIENE UN AGENTE O COMPUESTO CAPAZ DE INHIBIR LA FORMACION DE LOS PRODUCTOS FINALES DE LA GLUCOSILACION AVANZADA DE LA PROTEINA-OBJETIVO, MEDIANTE REACCION CON EL GRUPO CARBONILO DEL PRODUCTO FORMADO EN LAS PRIMERAS ETAPAS DE LA GLUCOSILACION DE DICHAS PROTEINAS. LOS AGENTES ADECUADOS PUEDEN CONTENER UN GRUPO NITROGENADO ACTIVO, COMO UN GRUPO HIDRAZINA, Y PUEDEN TAMBIEN DERIVARSE, AL MENOS EN PARTE, DE AMINOACIDOS. ALGUNOS AGENTES ESPECIFICOS SON AMINOGUANIDINA, ALFA-HIDRAZINOHISTIDINA Y LISINA. EL METODO REQUIERE PONER EN CONTACTO LA PROTEINA-OBJETIVO CON EL PREPARADO. SE EXPONEN ALGUNAS APLICACIONES INDUSTRIALES Y TERAPEUTICAS DE LA INVENCION Y COMO PUEDE TRATARSE EL DETERIORO DE ALIMENTOS Y EL ENVEJECIMIENTO DE PROTEINAS ANIMALES.
ES86115332T 1985-11-14 1986-11-05 Procedimiento y agentes para la inhibicion del envejecimiento de las proteinas. Expired - Lifetime ES2061435T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/798,032 US4758583A (en) 1984-03-19 1985-11-14 Method and agents for inhibiting protein aging

Publications (1)

Publication Number Publication Date
ES2061435T3 true ES2061435T3 (es) 1994-12-16

Family

ID=25172357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86115332T Expired - Lifetime ES2061435T3 (es) 1985-11-14 1986-11-05 Procedimiento y agentes para la inhibicion del envejecimiento de las proteinas.

Country Status (6)

Country Link
US (1) US4758583A (es)
EP (1) EP0222313B1 (es)
JP (2) JPH0667827B2 (es)
AT (1) ATE112165T1 (es)
DE (1) DE3650080T2 (es)
ES (1) ES2061435T3 (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262152A (en) * 1984-03-19 1993-11-16 The Rockefeller University Amidrazones and derivatives thereof
US5852009A (en) * 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US5612332A (en) * 1984-03-19 1997-03-18 Alteon Inc. Di- and triaminoguanidines, and methods of use
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5128122A (en) * 1984-03-19 1992-07-07 The Rockefeller University Method and agents for preventing staining of teeth
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5476849A (en) * 1984-03-19 1995-12-19 The Rockefeller University Methods for glycosylation inhibition using amino-benzoic acids and derivatives
US4983604A (en) * 1987-11-13 1991-01-08 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5254593A (en) * 1984-03-19 1993-10-19 The Rockefeller University Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking
US5514676A (en) * 1984-03-19 1996-05-07 The Rockefeller University Amino-benzoic acids and derivatives, and methods of use
US5218001A (en) * 1984-03-19 1993-06-08 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
USRE35465E (en) * 1984-03-19 1997-02-25 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5114943A (en) * 1984-03-19 1992-05-19 The Rockefeller University Amino-substituted pyrimidines, derivatives and methods of use therefor
US4900747A (en) * 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5137916A (en) * 1985-11-14 1992-08-11 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5811075A (en) * 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US5468777A (en) * 1984-03-19 1995-11-21 The Rockefeller University Method and agents for preventing and reversing the staining of teeth
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US5356895A (en) * 1984-03-19 1994-10-18 The Rockefeller University 1,4 piperizino inhibitors of non-enzymatic cross-linking of proteins
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5534540A (en) * 1984-03-19 1996-07-09 Alteon Inc. Methods of inhibiting the advanced glycosylation of proteins using tetramic and tetronic acids and compositions therefor
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US4978684A (en) * 1987-11-13 1990-12-18 The Rockefeller University Method and agents for preventing staining of teeth
US5399560A (en) * 1984-03-19 1995-03-21 The Rockefeller University 1,2,4-triazine products resulting from the inhibition of advanced glycosylation
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US5017696A (en) * 1987-09-17 1991-05-21 The Rockefeller University Advanced glycosylation end products and associated methods
US5126442A (en) * 1987-09-17 1992-06-30 The Rockefeller University Advanced glycosylation endproducts and associated methods
EP0323590A3 (en) * 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
EP0325936A3 (en) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidine derivatives and inhibitory agents on maillard reaction containing them as active ingredients
CA1332572C (en) * 1988-01-29 1994-10-18 Anthony Cerami Method and agents for preventing staining of teeth
EP0339496A3 (en) * 1988-04-26 1991-05-08 Ono Pharmaceutical Co., Ltd. Aminoguanidine derivatives
JP2817219B2 (ja) * 1988-09-08 1998-10-30 武田薬品工業株式会社 カルバジン酸誘導体、その製造法及び製剤
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
ATE83658T1 (de) * 1988-11-25 1993-01-15 Lubec Gert Behandlung von durch glucose ausgeloester quervernetzung von collagen bei diabetes mellitus-patienten durch arginin, spermidin, kreatin oder agmatin.
AT393079B (de) * 1989-03-06 1991-08-12 Lubec Gert Pharmazeutische verwendung von agmatin
AT393080B (de) * 1988-11-25 1991-08-12 Lubec Gert Pharmazeutische verwendung von arginin (salzen)
US5132230A (en) * 1989-03-28 1992-07-21 Isolab, Inc. Primary standard and method of making secondary standards for calibration of glycated protein assays
US5108930A (en) * 1990-02-20 1992-04-28 Alteon Inc. Aminoguanidine assay and applications thereof
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
TW221689B (es) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
US5710181A (en) * 1991-12-16 1998-01-20 Washington University Inhibition of nitric oxide formation in inflammatory bowel disease
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5837738A (en) * 1991-12-16 1998-11-17 Washington University Method of inhibiting nitric oxide formation
US5246970A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
EP0547558B1 (en) * 1991-12-16 2000-04-19 Washington University Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
ATE183086T1 (de) * 1992-04-15 1999-08-15 Alteon Inc Aminoguanidin-spruehtrocknungsverfahren
DE4222980A1 (de) * 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
CA2145418A1 (en) 1992-09-29 1994-04-14 John S. Patton Pulmonary delivery of active fragments of parathyroid hormone
US5453514A (en) * 1992-12-25 1995-09-26 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors
US5500439A (en) * 1993-12-09 1996-03-19 Alteon Inc. Aminopyrazoles
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
WO1995020979A1 (en) * 1994-02-03 1995-08-10 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
EP2036541A1 (en) 1994-03-07 2009-03-18 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
JP3333309B2 (ja) * 1994-04-08 2002-10-15 鐘淵化学工業株式会社 ケトアミン含有タンパク質吸着体
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
WO1996012483A1 (en) * 1994-10-25 1996-05-02 Washington University Method of inhibiting nitric oxide formation
US5994577A (en) * 1994-11-23 1999-11-30 Larsen; Scott D. Aminoguanidine carboxylates for the treatment of non-insulin-dependent diabetes mellitus
PT793646E (pt) * 1994-11-23 2002-03-28 Biovitrum Ab Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente
US5698563A (en) * 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
US5661139A (en) * 1995-01-13 1997-08-26 Alteon Inc. Bis-(2-aryl) hydrazones
NZ302027A (en) * 1995-01-18 2001-04-27 Picower Inst Med Res Thiazolium compounds and their use in pharmaceutical compositions
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
JP3542665B2 (ja) * 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5850840A (en) * 1995-11-15 1998-12-22 Alteon Inc. Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US6110968A (en) * 1995-12-26 2000-08-29 The Picower Institute For Medical Research Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
DK0888293T3 (da) * 1995-12-26 2002-04-22 Alteon Inc N-acylaminoalkylhydrazin-carboximidamider
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
US5869527A (en) * 1995-12-29 1999-02-09 Alteon Inc. 6-(N-carboxymethylamino)caproate, salts thereof and methods of use therefor
US5932578A (en) 1996-03-28 1999-08-03 Alteon Inc. Triazine compounds and methods of use therefor
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
EP0924294A3 (en) * 1997-09-09 1999-09-22 Rafael Rangel-Aldao Malt beverage having stabilized flavor and methods of production thereof
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6919326B1 (en) 1998-08-24 2005-07-19 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
CA2343357A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase assay: methods and materials
US6337065B1 (en) 1998-12-01 2002-01-08 University Of Kentucky Research Foundation Method for enhancing protective cellular responses to genotoxic stress in skin
KR100668928B1 (ko) * 1999-05-12 2007-01-12 도시오 미야타 혈중 카르보닐화합물 트랩제
HU227523B1 (en) 1999-10-06 2011-07-28 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7695903B2 (en) * 2000-05-23 2010-04-13 The University Of Southern California Low-density lipoprotein receptor related protein-1 (LRP-1)in clearance of alzheimer's amyloid-beta peptide from the central nervous system
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
ATE280766T1 (de) 2001-04-05 2004-11-15 Torrent Pharmaceuticals Ltd Heterocyclische verbindungen für alterungs und diabetes bedingte vasculare erkrankungen
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
JP4860906B2 (ja) 2002-03-08 2012-01-25 プロテミックス コーポレイション リミティド 心疾患および／または関連心不全の予防および／または治療
US6781039B2 (en) * 2002-05-07 2004-08-24 Stine Seed Farm, Inc. Soybean cultivar S010360
JP2006503014A (ja) * 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド 剤形及び関連する治療法
JP2006174845A (ja) * 2003-04-04 2006-07-06 House Foods Corp 食品中のアクリルアミドの低減方法
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
US7608586B2 (en) * 2003-06-11 2009-10-27 The University Of Rochester Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide
CA2550505A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
PT1778618E (pt) 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US9005643B2 (en) 2008-04-04 2015-04-14 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
TW201102380A (en) 2009-05-07 2011-01-16 Torrent Pharmaceuticals Ltd Novel heterocyclic compounds
WO2010144686A1 (en) 2009-06-10 2010-12-16 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
IT1403257B1 (it) * 2010-12-06 2013-10-17 Intercos Italiana Composizioni cosmetiche contenenti composti con azione anti-glicazione, da usare per prevenire e rallentare il processo di invecchiamento cutaneo
EP2664606B1 (en) 2012-04-25 2016-09-14 Ueno Fine Chemicals Industry, Ltd. An inhibitor of the production of advanced glycation end products
RU2634594C1 (ru) * 2016-11-30 2017-11-01 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Ингибиторы образования конечных продуктов гликирования на основе азопроизводных фенилсульфокислот
US20230210871A1 (en) 2017-10-12 2023-07-06 The Limited Company Research And Development Company "Medbiopharm" Use of sulfasalazine as an inhibitor of the formation of advanced glycation end products
KR102022338B1 (ko) * 2018-08-06 2019-09-18 이건무 당과 아미노산을 함유하는 안정한 수액제 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54138136A (en) * 1978-04-20 1979-10-26 Takio Izawa Decomposition preventing method by using amino acid type compound
US4629692A (en) * 1982-12-06 1986-12-16 Miles Laboratories, Inc. Immunoassay for nonenzymatically glucosylated proteins and protein fragments an index of glycemia
JPS6027371A (ja) * 1983-07-27 1985-02-12 Sanraku Inc 食品防腐剤
JPS60118174A (ja) * 1983-11-28 1985-06-25 Kazuji Fukunaga 変質防止法
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole

Also Published As

Publication number Publication date
JPS62142114A (ja) 1987-06-25
JPH0667827B2 (ja) 1994-08-31
US4758583A (en) 1988-07-19
DE3650080D1 (de) 1994-11-03
AU6495886A (en) 1987-05-21
EP0222313A3 (en) 1990-02-28
EP0222313B1 (en) 1994-09-28
AU610056B2 (en) 1991-05-16
ATE112165T1 (de) 1994-10-15
DE3650080T2 (de) 1995-02-16
JPH03103163A (ja) 1991-04-30
EP0222313A2 (en) 1987-05-20

Similar Documents

Publication Publication Date Title
ES2061435T3 (es) Procedimiento y agentes para la inhibicion del envejecimiento de las proteinas.
WO1993014750A3 (en) Amino acids useful as inhibitors of the advanced glycosylation of proteins
EP0316852A3 (en) Inhibitors of nonenzymatic cross-linking
NO982976D0 (no) N-acylaminoalkylhydrazinkarboksimidamider
RU94046295A (ru) L-аспартил-d- альфа -аминоалканоил-(s)-n-d-алкилбензиламиды, используемые в качестве искусственных подслащивающих агентов, пищевой состав, способ подслащивания пищевого состава
ATE114459T1 (de) Polyasparaginsäurederivate als überzugsmittel für arzneiformen und lebensmittel.
EP0327919A3 (en) Method and agents for preventing staining of teeth
EP0657520B1 (en) Antioxidant
AU6115494A (en) Adipocyte differentiation inhibitor peptide and adipocyte differentiation inhibitor containing said peptide as active ingredient
ATE129127T1 (de) Verfahren zum stabilisieren des geschmacksveränderungsmittels.
WO1996021450A3 (en) Bis-[hydrazones]
FR2422400A1 (fr) Nouvelles compositions destinees a l'elimination de certains parasites humains, a base de lipoaminoacides, caracterises par des chaines grasses comportant de 6 a 12 atomes de carbone
AU2825897A (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
IT8121867A0 (it) Prodotti di salificazione di acidi colici, processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo.
NO170011C (no) Analogifremgangsmaate til fremstilling av propanolaminderivater
DE69718775D1 (de) 1,2,4-triazinderivate zur inhibierung der proteinglycosylierung
ES2045092T3 (es) Un procedimiento de manufactura de un producto farmaceutico para tratamiento de cancer.
FI974601A (fi) Veren triglyseriditason kohoamista estävä peptidi ja mainittua peptidiä aktiivisena aineosana sisältävä veren triglyseriditason kohoamisen estäjä
ATE222066T1 (de) Mischungen aus gluten und laktose
ES8800686A1 (es) Un procedimiento para la preparacion de derivados aminoacidicos de l-fosfoserina.
ATE221897T1 (de) Inhibitoren der blutplättchen-aggregation, die c- terminale aminosäurereste mit aminergen seitenketten enthalten
ES2062317T3 (es) Procedimiento e intermedios para la preparacion de 3s-amino-2r-hidroxi-alcanoatos de isopropilo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 222313

Country of ref document: ES